Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96FN5
UPID:
KIF12_HUMAN
Alternative names:
-
Alternative UPACC:
Q96FN5; Q5TBE0
Background:
Kinesin-like protein KIF12 plays a pivotal role in cellular processes by participating in the intracellular transport system. Its precise mechanisms and pathways, however, remain to be fully elucidated. This protein's involvement in critical cellular functions makes it a subject of intense scientific study.
Therapeutic significance:
Kinesin-like protein KIF12 is linked to Cholestasis, progressive familial intrahepatic, 8 (PFIC8), a severe liver disorder. Understanding the role of Kinesin-like protein KIF12 could open doors to potential therapeutic strategies for treating this debilitating disease.